Srinivas Vourganti to Prostate-Specific Antigen
This is a "connection" page, showing publications Srinivas Vourganti has written about Prostate-Specific Antigen.
Connection Strength
0.543
-
Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers. Prostate. 2016 09; 76(13):1135-45.
Score: 0.143
-
Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int. 2015 Mar; 115(3):381-8.
Score: 0.127
-
Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples. Urology. 2011 Sep; 78(3):601-5.
Score: 0.102
-
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 08 01; 8(8):1128-1136.
Score: 0.055
-
Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer. 2022 09 15; 128(18):3287-3296.
Score: 0.055
-
Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagn Interv Radiol. 2014 May-Jun; 20(3):234-8.
Score: 0.031
-
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol. 2013 Nov; 190(5):1721-1727.
Score: 0.029